Sanofi SA
Key Metrics
How this company measures up on the fundamentals that matter
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $43 against a fair value of $62, a 31% discount. Passes all ethical screens. Ranks better than 97% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
What If You'd Bought SNY?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $42.50 | +2.5% | — | $1,025 | +2.5% |
| 2 Months | $44.30 | -1.7% | $2.42 | $1,038 | +3.8% |
| 3 Months | $41.34 | +5.4% | $2.42 | $1,113 | +11.3% |
| 6 Months | $46.29 | -5.9% | $2.42 | $994 | -0.6% |
| 1 Year | $47.26 | -7.8% | $2.42 | $973 | -2.7% |
| 2 Years | $44.33 | -1.7% | $4.63 | $1,087 | +8.7% |
| 3 Years | $44.60 | -2.3% | $6.67 | $1,127 | +12.7% |
| 5 Years | $43.42 | +0.4% | $10.62 | $1,248 | +24.8% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Latest Analysis — SNY
Timestamped intelligence from our daily research pipeline
Sanofi (SNY) — Accumulation at $44.25 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container {...
Sanofi (SNY) — Accumulation at $44.25 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container {...
Titan Research Desk | Week Ahead | 28 June 2026 Week Ahead: 42 Earnings, Nike’s Insider Signal, and the Defence Play Q3 opens with a concentrated week of corporate reporting....
12 June 2026 • Alpha Insights Sector Research Top 50 Healthcare Stocks Ranked: Pharma, Biotech, and MedTech Scored for Quality and Ethics Healthcare has become the quiet defensive rotation of...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-14